The Food and Drug Administration approved Infilbray, or venglustat, on November 18 for the neurological symptoms of Type 3 Gaucher disease in adults and children who weigh at least 15 kilograms. The agency called it the first drug approved to treat the neurological symptoms of the condition. The approval went to Genzyme Corporation, a Sanofi company, with orphan drug designation and priority review. Sanofi said the approval came ahead of the November 25 target action date.

The distinction matters because Gaucher disease has had a treatment for decades. Enzyme replacement therapy replaces the enzyme these patients lack, and it can control the enlargement of the liver and spleen and the blood abnormalities that come with the disease. What it does not do well is reach the brain. Type 3 Gaucher disease is the form that affects the brain, and until now the neurological part of the disease had no approved drug.

What Type 3 Gaucher disease does

Gaucher disease is an inherited lysosomal storage disorder. A mutation leaves the body short of an enzyme that breaks down a fatty substance called glucocerebroside. The substance accumulates in organs and tissues. In the most common form, the disease affects the liver, spleen, bone marrow, and bones. In Type 3, it also affects the central nervous system.

The neurological symptoms can include problems with eye movement, ataxia, and cognitive decline. The course varies. Some patients are diagnosed in childhood and have a slowly progressive form; others have more severe involvement. Enzyme replacement therapy can stabilize the systemic disease, which is why the trial enrolled patients whose bodies had already been stabilized. The brain remained the untreated part.

How venglustat works

Venglustat inhibits glucosylceramide synthase, an enzyme that makes a precursor of the substance that accumulates in Gaucher disease. The drug is designed to cross the blood-brain barrier, which enzyme replacement therapy does not do, and to reduce the accumulation of the harmful substance in the body and the brain.

The approved formulation is a tablet. In the trial, patients took it orally once a day. The FDA's announcement does not state the approved strength or dose, which are in the prescribing information.

The mechanism is substrate reduction rather than enzyme replacement. Instead of supplying the missing enzyme, the drug reduces the amount of material the body has to clear. That approach has been studied in several lysosomal storage disorders, and it has the advantage of reaching tissues that an infused enzyme cannot.

Substrate reduction is not new to Gaucher disease. Eliglustat, another glucosylceramide synthase inhibitor, is approved for the Type 1 form, which does not have the neurological involvement. The difference with venglustat is the design for the brain: the molecule was developed to cross the blood-brain barrier, and the trial was built around neurological endpoints rather than the systemic measures used in Type 1. That is why the approval is described as a first, even though the mechanism has a precedent.

The trial behind the approval

The approval rests on the LEAP2MONO Phase 3 study, a 52-week randomized, double-blind, multicenter trial of 43 patients aged 12 and older with Type 3 Gaucher disease. All had received enzyme replacement therapy and had stabilized systemic disease. Participants received oral venglustat once a day or intravenous enzyme replacement every two weeks.

At week 52, the venglustat group showed statistically significant superiority over imiglucerase enzyme replacement on a global test of neurological endpoints, with a p value of 0.0137. The endpoints were the modified Scale for the Assessment and Rating of Ataxia, known as mSARA, and the Repeatable Battery for the Assessment of Neuropsychological Status, known as RBANS, which measures cognition. The FDA release describes enzyme replacement as treating the non-neurologic manifestations of the disease, which is the comparison the trial was designed to make.

The release does not report a numerical effect size. That is the first thing a clinician will look for in the label and the publication, and it is the detail that determines how meaningful the improvement is for a given patient. A composite measure can improve because one component moved, and the size of the movement matters. The trial is also small, with 43 patients, which is typical for a rare disease but limits the precision of the estimate.

The two instruments behind the composite measure are well established. The mSARA is a clinician-rated scale for ataxia, scored on gait, stance, sitting, speech, and limb coordination. The RBANS is a brief cognitive battery that measures immediate and delayed memory, attention, language, and visuospatial ability. Both produce scores that can be compared over time, which is what a 52-week trial needs. Neither is a substitute for a patient's daily function, and the label will describe how the trial translated the scores into the endpoint that supported approval.

The comparison against enzyme replacement, rather than against placebo, is clinically sensible. Withdrawing enzyme therapy from a patient who needs it would be difficult to justify. It also means the trial measures venglustat against an active treatment, not against no treatment, which is a higher bar.

The trial population was also carefully defined. All 43 patients had received enzyme replacement and had stabilized systemic disease. That design isolates the neurological question, and it means the results may not describe patients who have not been on enzyme therapy or whose systemic disease is not controlled. A clinician reading the label will want to know how closely the trial population matches the patient in front of them.

The safety profile

The FDA's release lists gastrointestinal symptoms and mood-related adverse effects as commonly reported. Sanofi's announcement gives the trial figures: diarrhea in 14 percent of the venglustat group versus none in the enzyme replacement group, enlarged spleen in 14 percent versus none, nausea in 14 percent versus 5 percent, and depression in 10 percent versus none. The numbers are small because the trial is small, and they are the kind of comparison a family will want to discuss with the care team.

The label also carries serious warnings. The FDA's release flags suicidal ideation and behavior as a psychiatric risk. Sanofi's release describes warnings for suicidal ideation and behavior, lens opacification in pediatric patients, and embryofetal toxicity. The animal findings raised concerns about possible vision clouding in younger patients and about fetal harm during pregnancy. The label contains the full warnings and the monitoring guidance.

The psychiatric risk deserves attention in a disease that already affects the brain and in a patient population that includes children and adolescents. Families and clinicians will need to monitor mood and behavior, and the label's guidance on that monitoring is part of the information that should shape the decision to prescribe.

In the United States, anyone in crisis can call or text 988 to reach the Suicide and Crisis Lifeline.

The vision warning is specific enough to change the monitoring schedule: a pediatric patient on the drug will need eye examinations. The pregnancy warning is a reminder that the drug is not appropriate for everyone, and that the conversation with a care team has to include the patient's full situation.

What the approval means for patients

For a family managing Type 3 Gaucher disease, the approval adds an option for the part of the disease that enzyme therapy could not address. It does not replace enzyme therapy for the systemic disease, and it is not a cure. The trial enrolled patients whose systemic disease was already stabilized on enzyme replacement, which is the population the label is likely to describe most directly.

The care model around the drug is likely to be multidisciplinary. A neurologist will follow the ataxia and cognitive measures. A hematologist or metabolic specialist will manage the Gaucher disease overall. A psychiatrist or psychologist will be part of the conversation because of the mood-related risks. An ophthalmologist will monitor the pediatric patients for lens changes. That is a lot of coordination for a family, and it is the part of a rare disease approval that the announcement does not capture.

The practical questions are access and monitoring. Orphan drugs are expensive, and the release does not discuss price or coverage. The psychiatric and vision warnings mean the drug will require close follow-up. A family considering it should ask the care team about the expected benefit, the monitoring schedule, and what to do if mood changes appear.

The evidence gap

The approval is a first, and firsts in rare disease often arrive with less evidence than approvals in common conditions. The trial is randomized and double-blind, which is a strength. It is also small, short relative to the course of a chronic neurological disease, and summarized in the release without an effect size.

The questions that remain are the ones that matter to patients. How large is the cognitive benefit, and does it persist beyond a year? Does the drug change the trajectory of the disease or only the measured symptoms? What happens when it is started earlier or later? The label and the post-marketing record will fill in some of the answers. The release does not describe post-marketing requirements, and Sanofi has said the drug is under review in the European Union, Japan, and other jurisdictions, with additional filings planned through 2027.

Rare disease approvals often rest on smaller trials than approvals for common conditions, and regulators accept that tradeoff when the disease is serious and the options are limited. The tradeoff puts more weight on the label, the monitoring, and the post-marketing data. For a first drug in a neurological disease, the years after approval are part of the evidence base, not an afterthought.

The untreated part of the disease

Gaucher disease has had a treatment for the body for decades. The brain was the part that medicine could not reach, and for Type 3 patients that was the part that shaped the prognosis. The approval of venglustat changes that, with the caution that a first drug is a beginning rather than an answer.

The families who have been waiting for a treatment for the neurological symptoms now have a label to read and a conversation to have. The details in that label, the effect size, the monitoring, and the warnings, are the ones that will decide how much the approval changes a given patient's life.

Primary sources

  1. FDA press announcement of November 18, 2026, for the approval, the trial design, the results summary, the safety information, and the indication.
  2. Genzyme and Sanofi prescribing information, for the approved dose, warnings, and monitoring guidance.